Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension

A Randomized, Placebo-Controlled, Double-Blind, Six-Arm, Dose Escalation, Multi-Center Study to Evaluate the Efficacy and Safety of SLV306: 150, 300, 600 mg Once Daily, 150-300 mg Twice Daily and Amlodipine 5-10 mg Once Daily in Subjects With Hypertension

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00160212

Enrollment

Unknown

Registered

2005-09-12

Start date

2004-12-31

Completion date

Unknown

Last updated

2009-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

blood pressure

Brief summary

This study is to compare the efficacy and safety of increasing doses of SLV306 with amlodipine.

Interventions

DRUGDaglutril

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* sitting office diastolic blood pressure between 90 and 109 mmHg * office systolic blood pressure between 140 and 179 mmHg * mean day-time diastolic 24-h ABPM blood pressure \>= 85 mmHg inclusive at baseline

Exclusion criteria

* known secondary hypertension * decompensated congestive heart failure

Countries

Australia, Bulgaria, Denmark, Estonia, Germany, Hungary, Israel, Latvia, Lithuania, Slovakia, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026